| Date | Title | Description |
| 23.03.2026 | Everest Medicines Accelerates Global Ambitions with Key Acquisitions and Drug Launches | Everest Medicines is reshaping its market footprint. The biopharmaceutical giant secured rights to CARDAMYST™ (etripamil) nasal spray for Greater China. This innovative therapy targets paroxysmal supraventricular tachycardia (PSVT), offerin... |
| 23.03.2026 | Everest Medicines Enters into Asset Purchase Agreement with Corxel Pharmaceuticals to Develop and Commercialize CARDAMYST™ (Etripamil) Nasal Spray in Greater China | SHANGHAI, March 23, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of ... |
| 12.11.2024 | Milestone Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Regulatory and Corporate Update | NDA for CARDAMYST™ in PSVT under review by FDA; PDUFA March 27, 2025
MONTREAL and CHARLOTTE, N.C., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today reported financial results for the third quarter ended... |
| 29.10.2024 | Rezolve AI Leads Empathetic Conversational Commerce Revolution with Microsoft Endorsement, Applauds Sierra's $4.5 Billion Valuation as a Milestone for AI-Driven Engagement | NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Rezolve AI, (Nasdaq: RZLV) a pioneer in empathetic conversational commerce solutions, congratulates Sierra on its recent $4.5 billion valuation achieved through fundraising led by Greenoaks Capita... |
| 08.08.2024 | Milestone Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Regulatory and Corporate Update | – NDA for CARDAMYST™ in PSVT accepted by FDA in 2Q 2024; PDUFA in March 2025
– Cash of $83.3 million as of June 30, 2024 expected to fund operations into 2026
– Stuart Duty and Andrew Saik Appointed as Independent Board Directors
MONTREAL a... |
| 29.02.2024 | Milestone Pharmaceuticals Announces Pricing of $30.0 Million Public Offering of Common Shares and Pre-Funded Warrants | - |
| 17.10.2022 | Milestone Pharma’s nasal spray rapidly restores normal heart rhythm, achieving goal of key study | Milestone Pharmaceuticals said Monday that an experimental nasal-spray medicine acted quickly to treat people experiencing episodes of a rapid but non-fatal heart rate — more than doubling the conversion to normal heart rhythm and achieving... |
| 11.08.2021 | Milestone Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Clinical and Corporate Update
USA - English USA - English USA - English USA - English | |
| 17.05.2021 | Milestone Pharmaceuticals Announces Exclusive License Agreement with Ji Xing Pharmaceuticals to Develop and Commercialize Etripamil for PSVT in Greater China | |
| 17.05.2021 | Milestone Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Clinical, Regulatory, and Corporate Update | |
| 17.05.2021 | Milestone Pharmaceuticals Announces Late-Breaker Oral Presentation of NODE-301 Data at ACC.21 | |
| 30.03.2021 | MILESTONE PHARMACEUTICALS INC.
Milestone Pharmaceuticals : Announces First Patient Enrolled in the ReVeRA Study, its Phase 2 Trial of Etripamil in Atrial Fibrillation and Rapid Ventricular Rate | MONTREAL and CHARLOTTE, N.C., March 29, 2021 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced... |
| 29.03.2021 | Milestone Pharmaceuticals Announces First Patient Enrolled in the ReVeRA Study, its Phase 2 Trial of Etripamil in Atrial Fibrillation and Rapid Ventricular Rate | |
| 29.03.2021 | Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Clinical and Corporate Update | |
| 23.03.2021 | Top 10 Medical Technology (MedTech) startups in Canada | Medical technology (MedTech), an industry that combines the power of technology with the capabilities of modern medical practices, is a sector that can by no means be overlooked in the world today. From the simple stethoscope to highly adva... |
| 25.02.2021 | Milestone Pharmaceuticals to Present at Upcoming Investor Conferences | MONTREAL and CHARLOTTE, N.C., Feb. 25, 2021 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced ... |
| 06.01.2021 | MILESTONE SCIENTIFIC INC.
Milestone Scientific Inc. : Raises Revenue Guidance to Over $2 Million for Q4 2020 | ROSELAND, N.J., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE American:MLSS), a leading developer of computerized drug delivery instruments that provides virtually painless and precise injections, today raised revenue gu... |
| 06.01.2021 | Milestone Scientific Inc. : Raises Revenue Guidance to Over $2 Million for Q4 2020 | ROSELAND, N.J., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE American:MLSS), a leading developer of computerized drug delivery instruments that provides virtually painless and precise injections, today raised revenue gu... |
| 18.11.2020 | Milestone Pharmaceuticals Announces First Patient Enrolled in RAPID, a Pivotal Phase 3 Study of Etripamil in PSVT | |
| 13.11.2020 | Milestone Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Clinical and Corporate Update | |
| 22.09.2020 | Milestone Pharmaceuticals Strengthens Board of Directors with Two New Appointments | |
| 06.11.2019 | BDC spinout Amplitude Ventures closes half of newly-launched $200 million health fund | Amplitude Ventures, a Montréal-headquartered investment firm focused on health and the life sciences sectors has announced the launch of a targeted $200 million CAD venture fund. The firm is a spin-out of the Business Development Bank of Ca... |
| 09.05.2019 | Four biotech companies announce pricings of IPOs, looking to raise more than $300M | NextCure, based in Beltsville, Maryland, said Wednesday that it had priced its IPO of 5 million shares at $15 each. Montreal-based Milestone said it had priced its 5.5 million share IPO also at $15 per share. Cortexyme, based in South San F... |
| 26.10.2018 | Term Sheet — Friday, October 26 | THE RISE OF THE BILLION-DOLLAR FUND
Good morning, Term Sheet readers.
Paid Content Why you must incorporate A.I. now—or risk getting disrupted From C3.ai
This influx of capital makes sense given that the bulk of venture capital funds raised... |
| 25.10.2018 | Milestone Pharmaceuticals Raises $80M in Equity Funding | Milestone Pharmaceuticals, a Montreal, Canada-based late-stage biopharmaceutical company developing interventions for tachycardias, completed an $80m equity financing.
The round was led by RTW Investments, with participation from Venrock He... |
| 02.08.2017 | Term Sheet — Wednesday, Aug. 2 | ET CETERA
OUT: Irene Rosenfeld will step down as CEO of Mondelez International in March, Fortune’s Beth Kowitt reports. Dirk Van de Put, currently the president and CEO of Mondelez-owned McCain Foods will take over.
Paid Content Securing th... |
| 01.08.2017 | Tekla Capital Joins $55M Series C for Milestone Pharmaceuticals | Milestone Pharmaceuticals Montreal, Canada, Inc., a clinical stage cardiovascular company, today announced the completion of a US$55 million Series C financing. The round was led by Novo Holdings A/S, and included new investors Forbion Capi... |
| 01.08.2017 | Milestone Pharmaceuticals Montreal Canada Completes US$55M Series C Financing | Milestone Pharmaceuticals Montreal, Canada, Inc., a Montreal, Canada-based clinical stage cardiovascular company, completed a US$55m Series C financing.
The round was led by Novo Holdings A/S, with participation from new investors Forbion C... |
| 01.08.2017 | Domain Associates Joins $55M Series C for Milestone Pharmaceuticals | Milestone Pharmaceuticals Montreal, Canada, Inc., a clinical stage cardiovascular company, today announced the completion of a US$55 million Series C financing. The round was led by Novo Holdings A/S, and included new investors Forbion Capi... |
| 01.08.2017 | Milestone Pharmaceuticals Closes $55 Million Series C Financing | |
| 15.06.2015 | Daily funding roundup - June 15, 2015 | Milestone Pharmaceuticals landed $17M; Lavu secured $15M; Scancam snapped $500K
Anti-fuel theft startup Scancam snapped up $500,000 in seed funding in order to roll out its technology across Australia. The Perth-based company manufactures a... |
| 15.06.2015 | Milestone Pharmaceuticals Closes US$17 Million Series B Financing to Complete Phase 2 Clinical Studies for MSP-2017 | |
| 15.06.2015 | Milestone Pharmaceuticals Closes US$17M Series B Financing | Milestone Pharmaceuticals Inc., a Saint-Laurent, Canada-based clinical stage cardiovascular company in Phase 2, closed a US$17m Series B financing.
The round was led by Domain Associates with participation from existing investors Fonds de s... |
| 15.06.2015 | Today in funding: Snug Vest, Milestone Pharmaceuticals, Lending Loop | A first-time entrepreneur and a new startup one year in the making are finally seeing their hard work pay off. Here’s the latest on who raised how much, from whom.
Snug Vest raises $500,000 in seed stage funding
Snug Vest, an affiliate of V... |
| 13.06.2011 | Milestone Pharmaceuticals Completes $13M Equity Financing | Milestone Pharmaceuticals Inc., a Montreal (Quebec), Canada-based cardiovascular drug development company, completed a $13m round of equity financing.
The round was led by Pappas Ventures, the Business Development Bank of Canada (BDC), and ... |
| 07.08.2007 | Life sciences briefing: Tuesday, Aug. 7, 2007 | (UPDATED at 12:30pm PT — see below.)
Featured companies: Capnia, AutekBio, Novacta Biosystems, XLHealth, Leprechaun, Agility Healthcare Solutions, AM Pharma, Milestone Pharmaceuticals, ChanTest
Capnia names former Alza head as CEO — The tin... |
| - | Four biotech companies announce pricings of IPOs, looking to raise more than $300M | Four biotechnology companies were looking to raise a combined $303.9 million starting on Thursday as they announced Wednesday the pricings of their initial public offerings.
The companies – NextCure, Milestone Pharmaceuticals, Cortexyme and... |
